The present invention relates to use of biomarkers of dry eye disease, and use of the biomarkers for selection of subjects for treatment and treatment of dry eye disease.

A system and method is provided for processing a positron emission tomography (PET) image of a subject having received a dose of a radiotracer that serves as chemical analog of an MC-I inhibitor. Specifically, the processing may includes identifying portions of the at least one PET image that represent MC-I expression levels.

Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RARα) in subjects in need thereof.

A biosensor, including a modified gold electrode and a macrophage RAW264.7 immobilized on the modified gold electrode. The disclosure also provides a method of preparing the biosensor and a method of using the same for evaluation of antioxidant capacity of substances.

The present invention provides a method of measuring the quality of therapeutic cells through real-time glutathione monitoring.

The present invention relates to a method for determining the distinctive nutritional requirements of a patient with specific nutritional needs and providing a composition meeting the distinctive nutritional requirements of said patient.

The present invention relates to a real-time fluorescence imaging sensor for measuring glutathione in cell organelles and a method for fabricating the same. More specifically, the present invention relates to a novel compound for measuring glutathione in cell organelles, a method for preparing the novel compound, a real-time fluorescence imaging sensor for measuring glutathione in cell organelles, which comprises the novel compound, a method for fabricating the imaging sensor, and a method of measuring glutathione in cell organelles by use of the imaging sensor. When the composition comprising the compound according to the present invention is used, it can measure the antioxidant activity of the organelle mitochondria or Golgi apparatus in living cells, particularly stem cells, and can screen highly active stem cells based on the results obtained by measuring the antioxidant activity of the cell organelle.

Managing and treating elevated OS biomarkers in mammals such as companion animals with at least one of the supplements alpha-lipoic acid, carnitine, co-enzyme Q-10, ginger, green tea, licorice, milk thistle, garlic, honey. resveratrol, soybeans, tomatoes, turmeric, vitamin D, vitamin E, or selenium. Other compounds are Zinc, Vitamin E, Vitamin C, Quercetin, L-glutamine and Robuvit. Diagnosing an oxidative stress (OS) in a mammal detects an OS biomarker, selectively isoprostane and other antioxidant biomarkers such as HODE, microRNAs, TAC, GSH, MDA, and TNF-alpha. The sample can be saliva.

The present invention relates to a method for determining the distinctive nutritional requirements of a patient with specific nutritional needs and providing a composition meeting the distinctive nutritional requirements of said patient.

The present invention provides biomarkers of oxidative stress in subjects with retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, Fuchs' dystrophy, diabetic macular edema (DME), geographic atrophy, Stargardt's disease, or retinal vein occlusion (RVO), and their use in identifying subjects in need of treatment and methods for staging the severity of the disease.